CY1112475T1 - Υποκατεστημενες 2-καρβονυλαμινο-6-πιπεριδιναμινο πυριδινες και υποκατεστημενα 1-καρβονυλαμινο-3-πιπεριδιναμινοβενζολια ως αγωνιστες 5-ητ1f - Google Patents

Υποκατεστημενες 2-καρβονυλαμινο-6-πιπεριδιναμινο πυριδινες και υποκατεστημενα 1-καρβονυλαμινο-3-πιπεριδιναμινοβενζολια ως αγωνιστες 5-ητ1f

Info

Publication number
CY1112475T1
CY1112475T1 CY20121100254T CY121100254T CY1112475T1 CY 1112475 T1 CY1112475 T1 CY 1112475T1 CY 20121100254 T CY20121100254 T CY 20121100254T CY 121100254 T CY121100254 T CY 121100254T CY 1112475 T1 CY1112475 T1 CY 1112475T1
Authority
CY
Cyprus
Prior art keywords
substituted
hydrogen
alkyl
carbonylamine
cycloalkyl
Prior art date
Application number
CY20121100254T
Other languages
English (en)
Inventor
Maria-Jesus Blanco-Pillado
Michael Philip Cohen
Sandra Ann Filla
Kevin John Hudziak
Daniel Timothy Kohlman
Dana Rae Benesh
Frantz Victor
Yao-Chang Xu
Bai-Ping Ying
Deanna Piatt Zacherl
Deyi Zhang
Brian Michael Mathes
Original Assignee
Eli Lilly And Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly And Company filed Critical Eli Lilly And Company
Publication of CY1112475T1 publication Critical patent/CY1112475T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56—Nitrogen atoms
    • C07D211/58—Nitrogen atoms attached in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4468—Non condensed piperidines, e.g. piperocaine having a nitrogen directly attached in position 4, e.g. clebopride, fentanyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C04—CEMENTS; CONCRETE; ARTIFICIAL STONE; CERAMICS; REFRACTORIES
    • C04B—LIME, MAGNESIA; SLAG; CEMENTS; COMPOSITIONS THEREOF, e.g. MORTARS, CONCRETE OR LIKE BUILDING MATERIALS; ARTIFICIAL STONE; CERAMICS; REFRACTORIES; TREATMENT OF NATURAL STONE
    • C04B35/00—Shaped ceramic products characterised by their composition; Ceramics compositions; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
    • C04B35/622—Forming processes; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
    • C04B35/626—Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B
    • C04B35/63—Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B using additives specially adapted for forming the products, e.g.. binder binders
    • C04B35/632—Organic additives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Ceramic Engineering (AREA)
  • Manufacturing & Machinery (AREA)
  • Epidemiology (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Structural Engineering (AREA)
  • Materials Engineering (AREA)
  • Inorganic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Nutrition Science (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Η παρούσα εφεύρεση αφορά ενώσεις του τύπου Ι: (Ι) ένα φαρμακευτικά αποδεκτό άλας δια προσθήκης οξέος αυτής όπου· το Χ είναι C(R<3c>= ή Ν=· το R<1> είναι C2-C6 αλκύλιο, υποκατεστημένο C2-C6 αλκύλιο, C3-C7 κυκλοαλκύλιο, υποκατεστημένο C3-C7 κυκλοαλκύλιο, φαινύλιο, υποκατεστημένο φαινύλιο, ετερόκυκλος, ή υποκατεστημένος ετερόκυκλος· το R<2> είναι υδρογόνο, C1-C3 n-αλκύλιο, C3-C6 κυκλοαλκύλιο-C1-C3 αλκύλιο, ή μία ομάδα του τύπου II (II) δεδομένου ότι όταν το R<1> είναι C2-C6 αλκύλιο ή υποκατεστημένο C2-C6 αλκύλιο, το R<2> είναι υδρογόνο ή μεθύλιο· τα R<3a>, R3b, και, όταν το Χ είναι C(R<3c>)=, R<3c>, είναι έκαστο ανεξάρτητα υδρογόνο, φθορουπόλοιπο, ή μεθύλιο, δεδομένου ότι κανένα περισσότερο από ένα από τα R<3a>, R<3b> και R<3c> είναι δυνατόν να είναι διαφορετικά από υδρογόνο· το R<4> είναι υδρογόνο ή C1-C3 αλκύλιο· το R<5> είναι υδρογόνο, C1-C3 αλκύλιο, ή C3-C6 κυκλοαλκυλοκαρβονύλιο, δεδομένου ότι όταν το R<3a> είναι διαφορετικό από υδρογόνο, το R<5> είναι υδρογόνο· το R<6> είναι υδρογόνο ή C1-C6 αλκύλιο· και το n είναι ένας ακέραιος από 1 έως 6 συμπεριλαμβανομένου. Οι ενώσεις της παρούσας εφεύρεσης είναι χρήσιμες για την ενεργοποίηση υποδοχέων 5-ΗΤ1F, αναστέλλοντας νευρονική εξίδρωση πρωτεΐνης και για την θεραπευτική αγωγή ή πρόληψη ημικρανίας σε ένα θηλαστικό.
CY20121100254T 2003-09-12 2012-03-12 Υποκατεστημενες 2-καρβονυλαμινο-6-πιπεριδιναμινο πυριδινες και υποκατεστημενα 1-καρβονυλαμινο-3-πιπεριδιναμινοβενζολια ως αγωνιστες 5-ητ1f CY1112475T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US50278003P 2003-09-12 2003-09-12
EP04780442A EP1663971B1 (en) 2003-09-12 2004-09-03 Substituted 2-carbonylamino-6-piperidinaminopyridines and substituted 1-carbonylamino-3-piperidinaminobenzenes as 5-ht1f agonists

Publications (1)

Publication Number Publication Date
CY1112475T1 true CY1112475T1 (el) 2015-12-09

Family

ID=34434850

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20121100254T CY1112475T1 (el) 2003-09-12 2012-03-12 Υποκατεστημενες 2-καρβονυλαμινο-6-πιπεριδιναμινο πυριδινες και υποκατεστημενα 1-καρβονυλαμινο-3-πιπεριδιναμινοβενζολια ως αγωνιστες 5-ητ1f

Country Status (30)

Country Link
US (3) US7291632B2 (el)
EP (1) EP1663971B1 (el)
JP (1) JP4700614B2 (el)
KR (1) KR100777875B1 (el)
CN (1) CN1849307B (el)
AR (1) AR045619A1 (el)
AT (1) ATE538093T1 (el)
AU (1) AU2004280320B2 (el)
BR (1) BRPI0414241A (el)
CA (1) CA2537936C (el)
CR (1) CR8275A (el)
CY (1) CY1112475T1 (el)
DK (1) DK1663971T3 (el)
EA (1) EA011274B1 (el)
EC (1) ECSP066415A (el)
ES (1) ES2379665T3 (el)
IL (1) IL173521A (el)
MA (1) MA28212A1 (el)
MX (1) MXPA06002767A (el)
MY (1) MY144623A (el)
NO (1) NO20061584L (el)
NZ (1) NZ545049A (el)
PE (1) PE20050350A1 (el)
PL (1) PL1663971T3 (el)
PT (1) PT1663971E (el)
SI (1) SI1663971T1 (el)
TW (1) TWI340740B (el)
UA (1) UA82711C2 (el)
WO (1) WO2005035499A1 (el)
ZA (1) ZA200602072B (el)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI263497B (en) 2002-03-29 2006-10-11 Lilly Co Eli Pyridinoylpiperidines as 5-HT1F agonists
UA82711C2 (en) * 2003-09-12 2008-05-12 Эли Лилли Энд Компани Substituted 2-carbonylamino-6-piperidinaminopyridines and substituted 1-carbonylamino-3-piperidinaminobenzenes as 5-ht1f agonists
DE102005055892A1 (de) * 2005-11-22 2007-05-24 Henkel Kgaa Neue Kupplerkomponenten
KR101697801B1 (ko) * 2009-04-02 2017-01-18 코루시드 파마슈티컬즈 인코포레이티드 2,4,6-트리플루오로-ｎ-〔6-（1-메틸-피페리딘-4-카르보닐）-피리딘-2-일］-벤즈아미드의 조성물
KR20120069710A (ko) * 2009-09-08 2012-06-28 교린 세이야꾸 가부시키 가이샤 ４?(５?메틸피리딘?２?일아미노)피페리딘?１?카복실산 유도체의 제조방법
CA2795062A1 (en) 2010-04-02 2011-10-06 Colucid Pharmaceuticals, Inc. Compositions and methods of synthesis of pyridinoylpiperidine 5-ht1f agonists
WO2015014900A1 (en) * 2013-07-31 2015-02-05 Minoryx Therapeutics S.L. Di(hetero)arylamides and sulfonamides, methods for their preparation and therapeutic uses thereof
CN109596521A (zh) * 2018-02-11 2019-04-09 中国科学院海洋研究所 磷钼蓝分光光度法中还原剂的保存方法
WO2020038435A1 (en) * 2018-08-24 2020-02-27 Sunshine Lake Pharma Co., Ltd. Pyridinylmethylenepiperidine derivatives and uses thereof
AR119319A1 (es) 2019-07-09 2021-12-09 Lilly Co Eli Procesos e intermediario para la preparación a gran escala de hemisuccinato de 2,4,6-trifluoro-n-[6-(1-metil-piperidina-4-carbonil)-piridin-2-il]-benzamida y preparación de acetato de 2,4,6-trifluoro-n-[6-(1-metil-piperidina-4-carbonil)-piridin-2-il]-benzamida
CN110845402B (zh) * 2019-11-22 2023-05-09 广东东阳光药业有限公司 吡啶亚甲基哌嗪衍生物及其用途
CN111004214B (zh) * 2019-11-22 2021-06-08 广东东阳光药业有限公司 吡啶酰基哌啶衍生物及其用途
CN114728929A (zh) * 2019-11-22 2022-07-08 广东东阳光药业有限公司 吡啶亚甲基哌啶衍生物及其用途
CN113045540B (zh) * 2019-12-27 2024-02-13 上海天慈国际药业有限公司 一种拉司米地坦的制备方法

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5356904A (en) * 1992-10-07 1994-10-18 Merck & Co., Inc. Carbostyril oxytocin receptor antagonists
DE4320484A1 (de) * 1993-06-21 1994-12-22 Dornier Gmbh Steuerbares Supraleiter-Bauelement
US5521196A (en) 1994-10-05 1996-05-28 Eli Lilly And Company 5-HT1F agonists for the treatment of migraine
US5521197A (en) 1994-12-01 1996-05-28 Eli Lilly And Company 3-<1-alkylenearyl>-4-<1,2,3,6-tetrahydropyridinyl>-and 3-<1-alkylenearyl>-4-piperidinyl-1h-indoles: new 5-HT1F agonists
PL322843A1 (en) 1995-03-20 1998-02-16 Lilly Co Eli 5-substituted 3-91,2,3,6-tetrahydropyridin-4-yl)- and 3-9piperydin-4-4-yl0-1h-indoles nevel 5-htif natagonists
US5942536A (en) 1995-10-10 1999-08-24 Eli Lilly And Company N- 2-substituted-3-(2-aminoethyl)-1H-indol-5-YL!-Amides: new 5-HT1F agonists
US5708187A (en) 1996-06-27 1998-01-13 Eli Lilly And Company 6-substituted-1,2,3,4-tetrahydro-9H-carbazoles and 7-substituted-10H-cyclohepta 7,6-B!indoles: New 5-HT1F agonists
PT929299E (pt) 1996-08-28 2004-02-27 Lilly Co Eli 1,2,3,4-tetra-hidro-2-dibenzofuranaminas e 2-aminociclo-hepta ¬b| benzofuranos substituidos
JP2001501946A (ja) * 1996-10-08 2001-02-13 イーライ・リリー・アンド・カンパニー 新規セロトニン５―ｈｔ▲下１ｆ▼アゴニスト
ZA979961B (en) 1996-11-15 1999-05-05 Lilly Co Eli 5-HT1F agonists
EP0875513A1 (en) 1997-04-14 1998-11-04 Eli Lilly And Company Substituted heteroaromatic 5-HT 1F agonists
ID23053A (id) 1997-06-04 2000-01-20 Lilly Co Eli Karboksamida yang digunakan sebagai agonis 5-ht <if>
US5905084A (en) 1997-11-14 1999-05-18 Eli Lilly And Company 5-HTIF -agonists effective in treating migraine
WO2000000490A2 (en) 1998-06-26 2000-01-06 Eli Lilly And Company 5-ht1f agonists
AU4831899A (en) 1998-06-30 2000-01-17 Eli Lilly And Company 5-HT1F agonists
US6608079B1 (en) 1998-12-11 2003-08-19 Eli Lilly And Company Indole derivatives and their use as 5-HT1F agonists
ES2295017T3 (es) 1999-02-10 2008-04-16 Eli Lilly And Company Agonistas 5-ht1f.
PL350864A1 (en) 1999-02-26 2003-02-10 Lilly Co Eli 5-ht1f
EP1264820A4 (en) * 2000-03-14 2004-09-15 Fujisawa Pharmaceutical Co amide compounds
TWI263497B (en) * 2002-03-29 2006-10-11 Lilly Co Eli Pyridinoylpiperidines as 5-HT1F agonists
BRPI0409211A (pt) * 2003-04-18 2006-03-28 Lilly Co Eli composto, composição farmacêutica, métodos para ativar receptores 5-ht1f, para inibir extravasão de proteìna neuronial, e para o tratamento ou prevenção de enxaqueca em um mamìfero, e, uso de um composto
UA82711C2 (en) * 2003-09-12 2008-05-12 Эли Лилли Энд Компани Substituted 2-carbonylamino-6-piperidinaminopyridines and substituted 1-carbonylamino-3-piperidinaminobenzenes as 5-ht1f agonists

Also Published As

Publication number Publication date
SI1663971T1 (sl) 2012-05-31
ES2379665T3 (es) 2012-04-30
JP4700614B2 (ja) 2011-06-15
CA2537936A1 (en) 2005-04-21
AR045619A1 (es) 2005-11-02
CR8275A (es) 2006-06-06
CA2537936C (en) 2013-03-12
US20110034511A1 (en) 2011-02-10
ECSP066415A (es) 2006-09-18
PT1663971E (pt) 2012-03-21
PL1663971T3 (pl) 2012-05-31
KR100777875B1 (ko) 2007-11-28
MA28212A1 (fr) 2006-10-02
KR20060087554A (ko) 2006-08-02
US7803813B2 (en) 2010-09-28
CN1849307B (zh) 2011-08-03
AU2004280320B2 (en) 2010-02-18
US20060287363A1 (en) 2006-12-21
PE20050350A1 (es) 2005-05-17
US7291632B2 (en) 2007-11-06
ATE538093T1 (de) 2012-01-15
NO20061584L (no) 2006-06-06
JP2007505105A (ja) 2007-03-08
TWI340740B (en) 2011-04-21
UA82711C2 (en) 2008-05-12
CN1849307A (zh) 2006-10-18
WO2005035499A1 (en) 2005-04-21
DK1663971T3 (da) 2012-03-19
US20070270466A1 (en) 2007-11-22
EA200600570A1 (ru) 2006-12-29
EP1663971A1 (en) 2006-06-07
ZA200602072B (en) 2007-09-26
NZ545049A (en) 2009-06-26
EP1663971B1 (en) 2011-12-21
IL173521A (en) 2012-10-31
AU2004280320A1 (en) 2005-04-21
TW200521113A (en) 2005-07-01
BRPI0414241A (pt) 2006-11-07
MY144623A (en) 2011-10-14
MXPA06002767A (es) 2006-06-14
IL173521A0 (en) 2006-07-05
EA011274B1 (ru) 2009-02-27

Similar Documents

Publication Publication Date Title
CY1112475T1 (el) Υποκατεστημενες 2-καρβονυλαμινο-6-πιπεριδιναμινο πυριδινες και υποκατεστημενα 1-καρβονυλαμινο-3-πιπεριδιναμινοβενζολια ως αγωνιστες 5-ητ1f
CY1105899T1 (el) Πυριδινοϋλοπιπepιδινες ως 5-ht1f αγωνιστες
CY1113099T1 (el) Παραγωγα (θειο)καρβαμοϋλ-κυκλοεξανιου ως ανταγωνιστες των υποδοχεων d3/d2
NO20052580L (no) Blandinger for behandling av infeksjon av Flavivirida viruser
CY1105554T1 (el) Παραγωγα 3-υποκατεστημενης-4-πυριμιδονης
NO20021528D0 (no) Kinuklidinforbindelser og medikamenter inneholdende de samme som den aktive bestanddel
ATE556058T1 (de) 1-(2h)-isochinolonderivat
HRP20070430T3 (en) (3-oxo-3,4-dihydro-quinoxalin-2-yl-amino)-benzamide derivatives and related compounds as glycogen phosphorylase inhibitors for the treatment of diabetes and obesity
NO20060219L (no) Forbindelser
DK1427720T3 (da) 3-substitueret-4-pyrimidonderivater
WO2006113552A8 (en) Cyanoarylamines
NO20082630L (no) Vann-opploslige benzoazepinforbindelser og farmasoytisk forbindelse
HUP0402019A2 (hu) CCR5 antagonistaként alkalmazható piperidinszármazékok és ezeket tartalmazó gyógyszerkészítmények
EA200300982A1 (ru) Гетероциклические производные для лечения рака и других пролиферативных заболеваний
ATE429429T1 (de) Pharmazeutisches verfahren und damit hergestellte verbindungen
WO2003082861A3 (en) Morpholinyl-urea derivatives for use of the treatment of inflammatory diseases
ATE366248T1 (de) N-aryl-substituiertes cyclisches aminderivat und medizin, die dieses als wirkstoff enthält
DE602006010702D1 (de) Homomorpholinoxazolidinone als antibakterielle mittel
CY1106940T1 (el) Μονοσακχαριδικα παραγωγα της αβερμεκτινης β1
DE60128329D1 (de) Pyrrolopyridazin-verbindungen
TR200401671T1 (tr) Piridin benzimidazol sülfinil bileşiklerinin sentesi sırasında oluşan sulfon analoglarının elimine edilmesi yöntemi
NO20045540L (no) Nye 3-(4-okso-4H-kromen-2-yl)-(1H)-kinolin-4-on-forbindelser, en fremgangsmate for deres fremstilling og farmasoytisk sammensetninger inneholdende dem
HUP0103327A2 (hu) Trombózis-ellenes hatású szubsztituált fenil-amidinek
NO20020291L (no) Terapeutiske og profylaktiske midler for neoplasmer
DE60223936D1 (de) Mittel zur anregung des appetits und mittel zur behandlung von anorexie